Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
141 hedge funds and large institutions have $829M invested in Achillion Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 62 increasing their positions, 38 reducing their positions, and 33 closing their positions.
110% more call options, than puts
Call options by funds: $27.3M | Put options by funds: $13M
63% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 38
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
11% less funds holding
Funds holding: 158 → 141 (-17)
13% less capital invested
Capital invested by funds: $950M → $829M (-$120M)
52% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$42.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.3M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.6M |
| 4 |
DM
Deerfield Management
New York
|
+$13.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$28.2M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.1M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$5.12M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$4.43M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$3.98M |
ACHN Hedge Fund Activity: Q3 2015 in Review
141 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q3 2015, worth a combined $829M — down 13% from $950M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of ACHN and 16 opened new positions — a net loss of 17 holders — while 38 trimmed existing stakes and 62 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $42.5M. The largest seller was AllianceBernstein, cutting an estimated $28.2M.
- 141 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q3 2015, down from 158 in Q2 2015.
- Funds reported $829M of Achillion Pharmaceuticals stock for Q3 2015, down 13% quarter-over-quarter.
- 16 funds opened new Achillion Pharmaceuticals positions in Q3 2015 and 33 closed out, a net change of -17 holders.
- The largest Achillion Pharmaceuticals buyer in Q3 2015 was OrbiMed, an estimated $42.5M added.
- The largest Achillion Pharmaceuticals seller in Q3 2015 was AllianceBernstein, an estimated $28.2M sold.
Based on aggregated 13F filings for Q3 2015.